FG-3019

Phase 2Small molecule

KKyntra Bio

FG-3019 is one of 181 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Chronic HepatitisActive, not recruiting

Pancreatic CancerActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Focal Segmental GlomerulosclerosisActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Focal Segmental GlomerulosclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

FG-3019

KKyntra Bio

Phase 2

3 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

Active Comparator

Moderna

Preclinical

1 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus3 trials

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Completed·KKyntra Bio·Phase 1·NCT00102297·20 enrolled

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Completed·KKyntra Bio·Phase 1·NCT00754143·38 enrolled

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Terminated·KKyntra Bio·Phase 2·NCT00913393·46 enrolled

Pancreatic Cancer3 trials

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Completed·KKyntra Bio·Phase 1/2·NCT02210559·37 enrolled

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed·KKyntra Bio·Phase 1·NCT01181245·50 enrolled

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·N/A·NCT02851381

Idiopathic Pulmonary Fibrosis2 trials

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Completed·KKyntra Bio·Phase 1·NCT00074698·21 enrolled

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Completed·KKyntra Bio·Phase 2·NCT01262001·90 enrolled

Chronic Hepatitis1 trial

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Terminated·KKyntra Bio·Phase 2·NCT01217632·114 enrolled

Focal Segmental Glomerulosclerosis1 trial

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Terminated·KKyntra Bio·Phase 1·NCT00782561·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for FG-3019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FG-3019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FG-3019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyntra Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKyntra Bio

FG-3019

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes Mellitus3 trials

Pancreatic Cancer3 trials

Idiopathic Pulmonary Fibrosis2 trials

Chronic Hepatitis1 trial

Focal Segmental Glomerulosclerosis1 trial

References

Drug Info

Quick Facts

Related News